Making personalized prostate cancer medicine a reality: Challenges and opportunities in the re-establishment of gold standards

Pakistan Journal of Pharmaceutical Sciences

Volumn 26, Issue 4, 2013, Pages 831-840

  Farooqi, Ammad Ahmad ^a   Butt, Ghazala ^b   Yousaf, Gohar ^a   Qadir, Muhammad Imran ^c   Shaukat, Uzma ^d   Mansoor, Qaisar ^d   Awan, Madeeha ^e   Bhatti, Shahzad ^e   Begum, Almas ^a  

^a RLMC   (Pakistan)

^b GCU   (Pakistan)

^c GC UNIVERSITY   (Pakistan)

^d INSTITUTE OF BIOMEDICAL AND GENETIC ENGINEERING IBGE   (Pakistan)

^e UNIVERSITY OF LAHORE   (Pakistan)

Author keywords

Apoptosis; Prostate cancer; Tmprss2 erg

Indexed keywords

ABIRATERONE ACETATE; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; BIOLOGICAL MARKER; CALCITRIOL; CALCIUM; DEATH RECEPTOR; DENOSUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRAMUSTINE PHOSPHATE; FOLIC ACID; GAMMA TOCOPHEROL; GONADORELIN; LYCOPENE; MIFEPRISTONE; MITHRAMYCIN; MITOXANTRONE; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRASTUZUMAB; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUNICAMYCIN; VITAMIN D;

AMINO TERMINAL SEQUENCE; APOPTOSIS; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RECURRENCE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; DISTANT METASTASIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION; GENE FUSION; GOLD STANDARD; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PAKISTAN; PERSONALIZED MEDICINE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CARCINOGENESIS; PROSTATE CARCINOMA; REVIEW; SOYBEAN; THROMBOCYTE; TRANSMEMBRANE PROTEASE SERINE 2; TUMOR XENOGRAFT;

HUMANS; INDIVIDUALIZED MEDICINE; MALE; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL; VITAMIN E;

EID: 84880299368     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Alix-Panabières C (2012). EPISPOT Assay: Detection of Viable DTCs/CTCs in Solid Tumor Patients. Recent Results Cancer Res., 195: 69-76.
2. Barve A, Khor TO, Reuhl K, Reddy B, Newmark H and Kong AN (2010). Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice. Nutr Cancer, 62(6): 789-94.
3. Benetti R, Gonzalo S, Jaco I, Muñoz P, Gonzalez S, Schoeftner S, Murchison E, Andl T, Chen T, Klatt P, Li E, Serrano M, Millar S, Hannon G and Blasco MA (2008). A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat. Struct. Mol. Biol., 15(3): 268-279.
4. Beuten J, Garcia D, Brand TC, He X, Balic I, Canby-Hagino E, Troyer DA, Baillargeon J, Hernandez J, Thompson IM, Leach RJ and Naylor SL (2009). Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis. J. Urol., 182(4): 1614-1620.
5. Bistulfi G, Foster BA, Karasik E, Gillard B, Miecznikowski J, Dhiman VK and Smiraglia DJ (2011). Dietary folate deficiency blocks prostate cancer progression in the TRAMP model. Cancer Prev. Res. (Phila). 4(11): 1825-1834.
6. Bobek V, Hoffman RM and Kolostova K (2012). Sitespecific cytomorphology of disseminated PC-3 prostate cancer cells visualized in vivo with fluorescent proteins. Diagn. Cytopathol., doi: 10.1002/dc.22843.
7. Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Böhm D, Scheble V, Sotlar K, Fend F, Tan SH, Dobi A, Kristiansen G, Wernert N and Perner S (2012). ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer-A comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis., doi: 10.1038/pcan.2011.67.
8. Braun M, Scheble VJ, Menon R, Scharf G, Wilbertz T, Petersen K, Beschorner C, Reischl M, Kuefer R, Schilling D, Stenzl A, Kristiansen G, Rubin MA, Fend F and Perner S (2011). Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer. Histopathology, 58(7): 1028-1036.
9. Braun M, Stomper J, Boehm D, Vogel W, Scheble VJ, Wernert N, Shaikhibrahim Z, Fend F, Kristiansen G and Perner S (2012). Improved method of detecting the erg gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization. J. Mol. Diagn., 14(4):322-7
10. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM and Netto GJ (2011). Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am. J. Surg. Pathol., 35(7): 1014-1020.
11. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M and Scher HI (2011). TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur. Urol., 60(5): 897-904.
12. Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, Sridhar SS, Knox JJ, Day JR, Groskopf J and Joshua AM (2011). Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. BJU Int. doi: 10.1111/j.1464-410X.2011.10922.x.
13. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P and Logothetis CJ (2011). Effects of abiraterone acetate on androgen signaling in castrateresistant prostate cancer in bone. J. Clin. Oncol., 30(6):637-43.
14. Falzarano SM, Zhou M, Carver P, Tsuzuki T, Simmerman K, He H and Magi-Galluzzi C (2011). ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch., 459(4): 441-447.
15. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R and Goessl C (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet, 377(9768): 813-822.
16. Fujiwara J, Sowa Y, Horinaka M, Koyama M, Wakada M, Miki T and Sakai T (2012). The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. Intl. J. Oncol., 40(5): 1483-1491.
17. Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin. Genitourin. Cancer, 9(1): 39-45.
18. Gonzalez-Moreno O, Segura V, Serrano D, Nguewa P, de las Rivas J and Calvo A (2007). Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo. Int. J. Cancer, 121(6): 1197-1204.
19. Groth A, Salnikov AV, Ottinger S, Gladkich J, Liu L, Kallifatidis G, Salnikova O, Ryschich E, Giese N, Giese T, Momburg F, Büchler MW, Moldenhauer G and Herr I (2012). New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting. Clin. Cancer Res., 18(4): 1028-1038.
20. Hahn T and Akporiaye ET (2012). Repeat dose study of the novel proapoptotic chemotherapeutic agent alphatocopheryloxy acetic acid in mice. Anticancer Drugs, 23(4): 455-464.
21. Hartung F, Stühmer W and Pardo LA (2011). Tumor cellselective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody. Mol. Cancer, 10: 109.
22. Hartung F, Stühmer W and Pardo LA (2011). Tumor cellselective apoptosis induction through targeting of K(V)10.1 via bifunctional TRAIL antibody. Mol. Cancer, 10: 109.
23. Heideker J, Prudden J, Perry JJ, Tainer JA and Boddy MN (2011). SUMO-targeted ubiquitin ligase, Rad60, and Nse2 SUMO ligase suppress spontaneous Top1-mediated DNA damage and genome instability. PLoS Genet., 7(3): e1001320
24. Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R and Chinnaiyan AM (2008). Characterization of TMPRSS2:ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res., 68: 73-80.
25. Ho CL, Liu IH, Wu YH, Chen LC, Chen CL, Lee WC, Chuang CH, Lee TW, Lin WJ, Shen LH and Chang CH (2011). Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumorbearing mice. J. Biomed. Biotechnol., 2011: 101497.
26. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, Skotheim RI, Peltola M, Smit F, Verhaegh G, Schalken J, Nees M and Kallioniemi O (2006). TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res., 66(21): 10242-10246.
27. Jiang HH, Kim TH, Lee S, Chen X, Youn YS and Lee KC (2011). PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials., 32(33): 8529-8537.
28. Jung YH, Lim EJ, Heo J, Kwon TK and Kim YH (2012). Tunicamycin sensitizes human prostate cells to TRAIL-induced apoptosis by upregulation of TRAIL receptors and downregulation of cIAP2. Intl. J. Oncol., doi: 10.3892/ijo.2012.1402.
29. Karpf AR and Matsui S (2005). Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res., 65(19): 8635-8639.
30. Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Navarro VN, Tagawa ST, Bander NH, Nanus DM and Giannakakou P (2012). Functional characterization of circulating tumor cells with a prostate-cancerspecific microfluidic device. PLoS One, 7(4): e35976.
31. Kogan Y, Halevi-Tobias K, Elishmereni M, Vuk-Pavlovic S and Agur Z (2012). Reconsidering the Paradigm of Cancer Immunotherapy by Computationally Aided Real-time Personalization. Cancer Res., 72(9):2218-27.
32. Konijeti R, Henning S, Moro A, Sheikh A, Elashoff D, Shapiro A, Ku M, Said JW, Heber D, Cohen P and Aronson WJ (2010). Chemoprevention of prostate cancer with lycopene in the TRAMP model. Prostate, 70(14): 1547-1554.
33. Kwee S, Song MA, Cheng I, Loo L and Tiirikainen M (2012). Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin. Transl. Sci., 5(1): 65-70.
34. Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, Gross ME and Kuhn P (2012). Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys. Biol., 9(1): 016002.
35. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK and Rosenfeld MG (2009). Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell, 139: 1069-1083.
36. Malmberg J, Sandström M, Wester K, Tolmachev V and Orlova A (2011). Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: Focus on 111In-and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody. Nucl. Med. Biol., 38(8): 1093-1102.
37. Man YG, Fu SW, Liu AJ, Stojadinovic A, Izadjoo MJ, Chen L and Gardner WA (2011). Aberrant expression of chromogranin A, miR-146a, and miR-146b-5p in prostate structures with focally disrupted basal cell layers: an early sign of invasion and hormonerefractory cancer? Cancer Genomics Proteomics, 8(5): 235-244.
38. Mani RS, Iyer MK, Cao Q, Brenner JC, Wang L, Ghosh A, Cao X, Lonigro RJ, Tomlins SA, Varambally S and Chinnaiyan AM (2011). TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res., 71(16): 5387-5392.
39. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, Palanisamy N and Chinnaiyan AM (2009). Induced chromosomal proximity and gene fusions in prostate cancer. Science, 326: 1230.
40. McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G and Liu G (2011). Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol. Immunother., 61(7):1137-47
41. Min KJ, Jang JH, Lee JT, Choi KS and Kwon TK (2012). Glucocorticoid receptor antagonist sensitizes TRAILinduced apoptosis in renal carcinoma cells through upregulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J. Mol. Med. (Berl), 90(3): 309-319.
42. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, Brase JC, Liu AY, Schlüter H, Pantel K, Schumacher U, Bokemeyer C, Steuber T, Graefen M, Sauter G and Schlomm T (2011). ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin. Cancer Res., 17(18): 5878-5888.
43. Nilsson RJ, Balaj L, Hulleman E, van Rijn S, Pegtel DM, Walraven M, Widmark A, Gerritsen WR, Verheul HM, Vandertop WP, Noske DP, Skog J and Würdinger T (2011). Blood platelets contain tumor-derived RNA biomarkers. Blood, 118(13): 3680-3683.
44. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A and Itoh K (2010). A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol. Immunother., 59(7): 1001-1009.
45. Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K and Matsuoka K (2007). Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol. Res., 16(7): 341-349.
46. Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, Sasada T, Yamada A and Itoh K (2012). Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate, 72(8): 834-845.
47. Noguchi M, Uemura H, Naito S, Akaza H, Yamada A and Itoh K (2011). A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate, 71(5): 470-479.
48. O'Connell BC, Adamson B, Lydeard JR, Sowa ME, Ciccia A, Bredemeyer AL, Schlabach M, Gygi SP, Elledge SJ and Harper JW (2010). A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability. Mol. Cell, 40(4): 645-657.
49. Patil V, Gada K, Panwar R, Varvarigou A, Majewski S, Weisenberger A, Ferris C, Tekabe Y and Khaw BA (2010). Imaging small human prostate cancer xenografts after pretargeting with bispecific bombesinantibody complexes and targeting with high specific radioactivity labeled polymer-drug conjugates. Eur. J. Nucl. Med. Mol. Imaging, Pharmazie, 65(12): 922-923.
50. Ray R, Banks M, Abuzahra H, Eddy VJ, Persons KS, Lucia MS, Lambert JR and Holick MF (2012). Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine model. Anticancer Res., 32(3): 727-731.
51. Rezeli M, Végvári A, Fehniger TE, Laurell T and Marko-Varga G (2011). Moving towards high density clinical signature studies with a human proteome catalogue developing multiplexing mass spectrometry assay panels. J. Clin. Bioinforma., 1(1): 7.
52. Robert G, Jannink S, Smit F, Aalders T, Hessels D, Cremers R, Mulders PF and Schalken JA (2012). Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate, doi: 10.1002/pros.22546.
53. Roobol MJ, Haese A and Bjartell A (2011). Tumour markers in prostate cancer III: Biomarkers in urine. Acta Oncol., 50(Suppl. 1): 85-89.
54. Sajid S, Mohile SG, Szmulewitz R, Posadas E and Dale W (2011). Individualized decision-making for older men with prostate cancer: Balancing cancer control with treatment consequences across the clinical spectrum. Semin. Oncol., 38(2): 309-325.
55. Shaikhibrahim Z, Lindstrot A, Buettner R and Wernert N (2011). Analysis of laser-microdissected prostate cancer tissues reveals potential tumor markers. Int. J. Mol. Med., 28(4): 605-611.
56. Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Perner S and Wernert N (2012). The peripheral zone of the prostate is more prone to tumor development than the transitional zone: Is the ETS family the key? Mol. Med. Report, 5(2): 313-316.
57. Shigemizu D, Hu Z, Hung JH, Huang CL, Wang Y and DeLisi C (2012). Using functional signatures to identify repositioned drugs for breast, myelogenous leukemia and prostate cancer. PLoS Comput. Biol., 8(2): e1002347.
58. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R and Goessl C (2012). Denosumab and bone-metastasis-free survival in men with castrationresistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial. Lancet, 379(9810): 39-46.
59. So AY, Jung JW, Lee S, Kim HS and Kang KS (2011). DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. PLoS One, 6(5): e19503.
60. Tan Z, Chen P, Schneider N, Glover S, Cui L, Torgue J, Rixe O, Spitz HB and Dong Z (2012). Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int. J. Oncol., 40(6):1881-8.
61. Taylor DJ, Parsons CE, Han H, Jayaraman A and Rege K (2011). Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells. BMC Cancer, 11: 470.
62. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J and Chinnaiyan AM (2011). Urine TMPRSS2: ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med., 3(94): 94ra72.
63. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R and Chinnaiyan AM (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature, 448: 595-599.
64. Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB and Chinnaiyan AM (2006). TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res., 66: 3396-3400.
65. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA and Chinnaiyan AM (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science, 310: 644-648.
66. Torricelli P, Caraglia M, Abbruzzese A and Beninati S (2012).?-Tocopherol inhibits human prostate cancer cell proliferation by up-regulation of transglutaminase 2 and down-regulation of cyclins. Amino Acids, 44(1):45-51.
67. Toubaji A, Albadine R, Meeker AK, Isaacs WB, Lotan T, Haffner MC, Chaux A, Epstein JI, Han M, Walsh PC, Partin AW, De Marzo AM, Platz EA and Netto GJ (2011). Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod. Pathol., 24(11): 1511-1520.
68. Uemura H, Fujimoto K, Mine T, Uejima S, de Velasco MA, Hirao Y, Komatsu N, Yamada A and Itoh K (2010). Immunological evaluation of personalized peptide vaccination monotherapy in patients with castration-resistant prostate cancer. Cancer Sci., 101(3): 601-608.
69. Vanveldhuizen PJ, Zulfiqar M, Banerjee S, Cherian R, Saxena NK, Rabe A, Thrasher JB and Banerjee SK (2003). Differential expression of neuropilin-1 in malignant and benign prostatic stromal tissue. Oncol. Rep., 10(5): 1067-1071.
70. von Moos R and Skacel T (2012). Denosumab: First data and ongoing studies on the prevention of bone metastases. Recent Results Cancer Res., 192: 187-196.
71. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R, Ren C, Ayala G and Ittmann M (2011). Activation of NF-{kappa}B by TMPRSS2/ERG fusion isoforms through toll-like receptor-4. Cancer Res., 71(4): 1325-1333.
72. Wang JY, Swami S, Krishnan AV and Feldman D (2012). Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer. Prostate, 72(15):1628-37
73. Wu LY, Liu T, Hopkins MR, Davis WC and Berkman CE (2012). Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. Prostate, 72(14):1532-41.
74. Xiao L, Zhu XZ, Wang Y, Gong Y and Guo CC (2011). TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens. Zhonghua Bing Li Xue Za Zhi, 40(6): 392-396.
75. Yaskiv O, Zhang X, Simmerman K, Daly T, He H, Falzarano S, Chen L, Magi-Galluzzi C and Zhou M (2011). The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies. Am. J. Surg. Pathol., 35(7): 1062-1068.